Nov 16 (Reuters) – Johnson & Johnson said on Monday it had agreed to buy Texas-based biotech Ollin Biosciences, expanding its pipeline of eye disease therapies.
Johnson & Johnson will acquire Ollin for $2.2 billion upfront, with the potential for regulatory and commercial milestone payments of up to about $1.13 billion, the drugmaker said.
Ollin, backed by investment firms ARCH Venture Partners and Mubadala Capital, was established in 2023 to develop treatments for vision-threatening diseases.
The deal is expected to close before the end of 2026.
(Reporting by Sneha S K in Bengaluru; Editing by Anil D’Silva and Joyjeet Das)

